Sequencing Nuances in MBC

CE / CME

Sequencing Nuances: Managing Complexities and Brain Metastases

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: March 27, 2025

Expiration: September 26, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

When discussing treatment plans with colleagues and patients, how confident are you in summarizing the recommended sequencing of HER2-targeted therapies for HER2+ MBC treatment based on the latest data and clinical guidelines?

2.

Case: Mary with metastatic HR-/HER2+ BC



  • Mary, 57, is diagnosed with metastatic HR-/HER2+ breast cancer with 1 small liver lesion

  • 24 mo after THP treatment, she progresses on maintenance HP with disease progression in the liver and develops 1 brain lesion

  • She then received T-DXd and had a partial response, but 8 mo later she has developed new liver metastases and MRI shows 3 new brain lesions

After local therapy to the brain, which of these regimens would you recommend for Mary now?

3.
Which of the following approaches would be appropriate to manage Bill's returning arthralgias?